The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera

British Journal of Haematology

Volumn 167, Issue 3, 2014, Pages 411-417

  Ancochea, Àgueda ^a   Álvarez Larrán, Alberto ^a   Morales Indiano, Cristian ^b   García Pallarols, Francesc ^a   Martínez Avilés, Luz ^c   Angona, Anna ^a   Senín, Alicia ^a   Bellosillo, Beatriz ^c   Besses, Carles ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Laboratori de Referencia de Catalunya   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Diagnostic criteria; Erythrocytosis; Erythropoietin; Essential thrombocythaemia; Polycythaemia vera

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; JANUS KINASE 2; BIOLOGICAL MARKER; EPO PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CHEMILUMINESCENT ENHANCED ENZYME IMMUNOASSAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME IMMUNOASSAY; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; JAK2 GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; BLOOD; DIFFERENTIAL DIAGNOSIS; GENETICS; MISSENSE MUTATION; POINT MUTATION; POLYCYTHEMIA; REPRODUCIBILITY; THROMBOCYTHEMIA, ESSENTIAL; VALIDATION STUDY;

ALLELES; AMINO ACID SUBSTITUTION; AREA UNDER CURVE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKOCYTE COUNT; MALE; MUTATION, MISSENSE; PLATELET COUNT; POINT MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84912012601     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13047     Document Type: Article

References (21)

1. Álvarez-Larrán, A., Ancochea, A., Angona, A., Pedro, C., García-Pallarols, F., Martínez-Avilés, L., Bellosillo, B. & Besses, C. (2012) Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica, 97, 1704-1707.
2. Birgegård, G. & Wide, L. (1992) Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol, 81, 603-606.
3. Carneskog, J., Kutti, J., Wadenvik, H., Lundberg, P.A. & Lindstedt, G. (1998) Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol, 60, 278-282.
4. Johansson, P.L., Safai-Kutti, S. & Kutti, J. (2005) An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol, 129, 701-705.
5. Jovanovic, J.V., Ivey, A., Vannucchi, A.M., Lippert, E., Oppliger Leibundgut, E., Cassinat, B., Pallisgaard, N., Maroc, N., Hermouet, S., Nickless, G., Guglielmelli, P., Van der Reijden, B.A., Jansen, J.H., Alpermann, T., Schnittger, S., Bench, A., Tobal, K., Wilkins, B., Cuthill, K., McLornan, D., Yeoman, K., Akiki, S., Bryon, J., Jeffries, S., Jones, A., Percy, M.J., Schwemmers, S., Gruender, A., Kelley, T.W., Reading, S., Pancrazzi, A., McMullin, M.F., Pahl, H.L., Cross, N.C., Harrison, C.N., Prchal, J.T., Chomienne, C., Kiladjian, J.J., Barbui, T. & Grimwade, D. (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 27, 2032-2039.
6. Larsen, T.S., Pallisgaard, N., Møller, M.B. & Hasselbalch, H.C. (2007a) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol, 79, 508-515.
7. Larsen, T.S., Christensen, J.H., Hasselbalch, H.C. & Pallisgaard, N. (2007b) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol, 136, 745-751.
8. Levine, R.L., Belisle, C., Waleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D.G. & Busque, L. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood, 107, 4139-4141.
9. Lindstedt, G. & Lundberg, P.A. (1998) Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemiavera and the assessment of EPO deficiency? Scand J Clin Lab Invest, 58, 441-458.
10. McMullin, M.F., Reilly, J.T., Campbell, P., Bareford, D., Green, A.R., Harrison, C.N. & Conneally, F. (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol, 138, 821-822.
11. Messinezy, M., Westwood, N.B., Woodcock, S.P., Strong, R.M. & Pearson, T.C. (1995) Low serum erythropoietin-a strong diagnostic criterion of primary polycythaemia even at normal haemoglobin levels. Clin Lab Haematol, 17, 217-220.
12. Messinezy, M., Westwood, N.B., El-Hemaidi, I., Marsden, J.T., Sherwood, R.S. & Pearson, T.C. (2002) Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol, 117, 47-53.
13. Mossuz, P., Girodon, F., Donnard, M., Latger-Cannard, V., Dobo, I., Boiret, N., Lecron, J.C., Binquet, C., Barro, C., Hermouet, S. & Praloran, V. (2004) Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica, 89, 1194-1198.
14. Pearson, T.C. & Messinezy, M. (1996) The diagnostic criteria of polycthemia rubra vera. Leukemia & Lymphoma, 22(suppl 1), 87-93.
15. Pearson, T.C., Guthrie, D.L., Simpson, J., Chinn, S., Barosi, G., Ferrant, A., Lewis, S.M. & Najean, Y. (1995) Interpretation of measured red cell mass and plasma volume in adults: expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol, 89, 748-756.
16. Remacha, A.F., Montserrat, I., Santamaria, A., Oliver, A., Barceló, M.J. & Parellada, M. (1997) Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica, 82, 406-410.
17. Spivak, J.L. & Silver, R.T. (2008) The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood, 112, 231-239.
18. Stein, B.L., Williams, D.M., Wang, N.Y., Rogers, O., Isaacs, M.A., Pemmaraju, N., Spivak, J.K. & Moliterno, A.R. (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica, 95, 1090-1097.
19. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
20. Tefferi, A., Thiele, J., Vannucchi, A.M. & Barbui, T. (2014) An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia, 28, 1407-1413.
21. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pardanani, A. & Tefferi, A. (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 22, 1299-1307.